// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis

B. Ghang - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Pirfenidone

Efficacy and safety of antifibrotic agents in idiopathic pulmonary fibrosis

L. Nuñez-García - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Instertitial lung disease and mycroscopic polyangiitis in chilean patients

P. Wurmann - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Interstitial lung disease in anca-associated vasculitis patients:comparison with idiopatic pulmonary fibrosis and interstitial pneumonia with autoimmune features

A. Abril - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Predictive factors for interstitial lung disease progression in patients with rheumatoid arthritis: a role for biological inflammation and disease modified anti rheumatic drugs (DMARDS

C. Lucas - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

The creation of artificial lungs from decellularized tissue

Woodring E Wright - International Conference on Tissue Engineering & Regenerative Medicine (ICTERM) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Ganciclovir

NLRP3 inflammasome activation in macrophages is mechanosensitive

Alison Almgren-Bell - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

The Wnt antagonist Dickkopf1(DKK1 promotes pulmonary fibrosis via M2-like macrophage polarization

Wook-Jin Chae - American Association of Immunologists (AAI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Mechanical stress modulates NLRP3 pathway in macrophages

Hemant Joshi - American Association of Immunologists (AAI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease

Sarah Tansley - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Idiopathic pulmonary fibrosis

N/A

FAM13A (Family with Sequence Similarity 13 Member A) Polymorphism Is Associated with Presence of a Radiographic Usual Interstitial Pneumonia Pattern in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Elana Bernstein - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease

Elena Joerns - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Interleukin

Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease

Daniel Kass - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases

Sara Remuzgo-Martinez - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

endothelin-1

Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

Veronica Pulito-Cueto - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Interstitial lung disease associated with systemic lupus erythematosus : a monocentric study of 23 cases

lou deneuville - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Mycophenolate mofetil

Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression

Kalliopi Domvri - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

ICAM-1

Impaired lung NK activity in the lung of Idiopathic Pulmonary Fibrosis patients

Tamara Cruz - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy

Miriana d'Alessandro - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

The effect of long-term personal air pollution exposure on the inflammatory mediators in Idiopathic Pulmonary Fibrosis

Tomos Ioannis - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Interleukin-10

Copyright © 2026. QuantiNova All rights reserved